Epitope mapping of Ebola virus dominant and subdominant glycoprotein epitopes facilitates construction of an epitope-based DNA vaccine able to focus the antibody response in mice

ABSTRACT We performed epitope mapping studies on the major surface glycoprotein (GP) of Ebola virus (EBOV) using Chemically Linked Peptides on Scaffolds (CLIPS), which form linear and potential conformational epitopes. This method identified monoclonal antibody epitopes and predicted additional epitopes recognized by antibodies in polyclonal sera from animals experimentally vaccinated against or infected with EBOV. Using the information obtained along with structural modeling to predict epitope accessibility, we then constructed 2 DNA vaccines encoding immunodominant and subdominant epitopes predicted to be accessible on EBOV GP. Although a construct designed to produce a membrane-bound oligopeptide was poorly immunogenic, a construct generating a secreted oligopeptide elicited strong antibody responses in mice. When this construct was administered as a boost to a DNA vaccine expressing the complete EBOV GP gene, the resultant antibody response was focused largely toward the less immunodominant epitopes in the oligopeptide. Taken together, the results of this work suggest a utility for this method for immune focusing of antibody responses elicited by vaccination.

[1]  J. Dye,et al.  Cooperativity Enables Non-neutralizing Antibodies to Neutralize Ebolavirus , 2017, Cell Reports.

[2]  L. Zeitlin,et al.  Structures of Ebola Virus GP and sGP in Complex with Therapeutic Antibodies , 2016, Nature Microbiology.

[3]  Erin E. H. Tran,et al.  Mapping of Ebolavirus Neutralization by Monoclonal Antibodies in the ZMapp Cocktail Using Cryo-Electron Tomography and Studies of Cellular Entry , 2016, Journal of Virology.

[4]  J. Dye,et al.  Macaque Monoclonal Antibodies Targeting Novel Conserved Epitopes within Filovirus Glycoprotein , 2015, Journal of Virology.

[5]  Jeffrey R. Kugelman,et al.  Emergence of Ebola Virus Escape Variants in Infected Nonhuman Primates Treated with the MB-003 Antibody Cocktail. , 2015, Cell reports.

[6]  J. Rucker,et al.  Mechanism of Binding to Ebola Virus Glycoprotein by the ZMapp, ZMAb, and MB-003 Cocktail Antibodies , 2015, Journal of Virology.

[7]  Kelly L Warfield,et al.  Codon-optimized filovirus DNA vaccines delivered by intramuscular electroporation protect cynomolgus macaques from lethal Ebola and Marburg virus challenges , 2015, Human vaccines & immunotherapeutics.

[8]  X. Qiu,et al.  Structures of protective antibodies reveal sites of vulnerability on Ebola virus , 2014, Proceedings of the National Academy of Sciences.

[9]  C. Badger,et al.  A multiagent filovirus DNA vaccine delivered by intramuscular electroporation completely protects mice from ebola and Marburg virus challenge , 2012, Human vaccines & immunotherapeutics.

[10]  Yoshihiro Kawaoka,et al.  Structure of an Antibody in Complex with Its Mucin Domain Linear Epitope That Is Protective against Ebola Virus , 2011, Journal of Virology.

[11]  J. Skehel,et al.  A Neutralizing Antibody Selected from Plasma Cells That Binds to Group 1 and Group 2 Influenza A Hemagglutinins , 2011, Science.

[12]  Kathryn L. Schornberg,et al.  The Primed Ebolavirus Glycoprotein (19-Kilodalton GP1,2): Sequence and Residues Critical for Host Cell Binding , 2009, Journal of Virology.

[13]  D. Burton,et al.  Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor , 2008, Nature.

[14]  Dafna M. Abelson,et al.  Complex of a protective antibody with its Ebola virus GP peptide epitope: unusual features of a V lambda x light chain. , 2008, Journal of molecular biology.

[15]  R. Meloen,et al.  Functional reconstruction and synthetic mimicry of a conformational epitope using CLIPS™ technology , 2007, Journal of molecular recognition : JMR.

[16]  W. Dowling,et al.  Influences of Glycosylation on Antigenicity, Immunogenicity, and Protective Efficacy of Ebola Virus GP DNA Vaccines , 2006, Journal of Virology.

[17]  A. Luxembourg,et al.  Enhancement of immune responses to an HBV DNA vaccine by electroporation. , 2006, Vaccine.

[18]  Kathryn L. Schornberg,et al.  Role of Endosomal Cathepsins in Entry Mediated by the Ebola Virus Glycoprotein , 2006, Journal of Virology.

[19]  D. A. Stein,et al.  Gene-Specific Countermeasures against Ebola Virus Based on Antisense Phosphorodiamidate Morpholino Oligomers , 2006, PLoS pathogens.

[20]  S. Whelan,et al.  Endosomal Proteolysis of the Ebola Virus Glycoprotein Is Necessary for Infection , 2005, Science.

[21]  P. Jahrling,et al.  Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys , 2003, The Lancet.

[22]  P. Jahrling,et al.  Comparison of the protective efficacy of DNA and baculovirus-derived protein vaccines for EBOLA virus in guinea pigs. , 2003, Virus research.

[23]  J. Wilson,et al.  Epitopes involved in antibody-mediated protection from Ebola virus. , 2000, Science.

[24]  P. Jahrling,et al.  DNA vaccines expressing either the GP or NP genes of Ebola virus protect mice from lethal challenge. , 1998, Virology.

[25]  M. Bray,et al.  Naked DNA vaccines expressing the prM and E genes of Russian spring summer encephalitis virus and Central European encephalitis virus protect mice from homologous and heterologous challenge , 1997, Journal of virology.